INHIBIKASE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.39 USD | +3.73% |
|
-18.71% | +9.45% |
Valuation
| Fiscal Period: December | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 69.35 | 12.61 | 7.841 | 9.003 | - | - |
| Enterprise Value (EV) 1 | 69.35 | 12.61 | 7.841 | 9.003 | 9.003 | 9.003 |
| P/E ratio | -19.7 x | -0.69 x | -0.36 x | -0.78 x | -1.03 x | -1.15 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 99.3 x | - | 30.1 x | - | - | 1.04 x |
| EV / Revenue | 99.3 x | - | 30.1 x | - | - | 1.04 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | -0.38 x | -0.28 x | -0.32 x |
| FCF Yield | - | - | - | -264% | -359% | -308% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,675 | 4,205 | 6,174 | 6,477 | - | - |
| Reference price 2 | 41.40 | 3.000 | 1.270 | 1.390 | 1.390 | 1.390 |
| Announcement Date | 21-03-31 | 23-03-31 | 24-03-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.6985 | - | 0.2605 | - | - | 8.64 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | - | -20.09 | -23.76 | -27.12 | -25.58 |
| Operating Margin | - | - | -7,712.01% | - | - | -296.03% |
| Earnings before Tax (EBT) 1 | - | - | -19.03 | -23.76 | -32.31 | -27.89 |
| Net income 1 | - | -18.05 | -19.03 | -23.76 | -27.03 | -25.51 |
| Net margin | - | - | -7,304.75% | - | - | -295.25% |
| EPS 2 | -2.100 | -4.320 | -3.570 | -1.780 | -1.345 | -1.205 |
| Free Cash Flow 1 | - | - | - | -23.76 | -32.31 | -27.71 |
| FCF margin | - | - | - | - | - | -320.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 21-03-31 | 23-03-31 | 24-03-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.0645 | 0.1164 | 0.0796 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.715 | -6.202 | -4.769 | -4.404 | -4.995 | -5.061 | -5.163 | -5.266 |
| Operating Margin | -7,307.73% | -5,328.06% | -5,993.31% | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | -4.178 | - | - | - | - |
| Net income 1 | -4.478 | -5.778 | -4.595 | -4.178 | -4.893 | -4.999 | -5.031 | -5.174 |
| Net margin | -6,940.14% | -4,963.47% | -5,775.04% | - | - | - | - | - |
| EPS 2 | -0.9600 | -1.110 | -0.8600 | -0.6400 | -0.7900 | -0.3700 | -0.3700 | -0.3800 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 23-05-15 | 23-08-14 | 23-11-14 | 24-03-27 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -23.8 | -32.3 | -27.7 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 21-03-31 | 23-03-31 | 24-03-27 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.39
USD
Average target price
17.5
USD
Spread / Average Target
+1,158.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.45% | 9M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- IKT Stock
- Financials Inhibikase Therapeutics, Inc.
